

pores could constitute only a very small percentage of the total cross-sectional area of the cell walls we examined.

Assuming that the pore diameters we measured represent the maximum size for free exchange between the plasma membrane and the environment, this value becomes an important consideration for many physiological functions as well as scientific manipulations. To cite a few examples, pore size may limit the effective size of toxins that function through binding to the plasma membrane (19) and of elicitors of phytoalexin synthesis (20), and pore size probably plays a role in a variety of other host-pathogen interactions, including recognition phenomena involving lectins (21). A limiting pore diameter must also be considered by researchers in their design of experiments involving the uptake of molecules (nucleic acids, proteins, oligosaccharides) by intact plant cells.

NICHOLAS CARPITA  
DARIO SABULARSE  
DAVID MONTEZINOS  
DEBORAH P. DELMER

*Plant Research Laboratory, Michigan State University—Department of Energy, and Department of Biochemistry, Michigan State University, East Lansing 48824*

#### References and Notes

1. A. Lauchli, in *Transport in Plants II*, U. Lüttge and M. G. Pitman, Eds. (Springer-Verlag, Berlin, 1976).
2. R. W. King, in *Transport and Transport Processes in Plants*, I. F. Wardlaw and J. B. Passioura, Eds. (Academic Press, New York, 1976).
3. J. J. Oertli, in *Water and Plant Life*, O. L. Lange, L. Kappen, E. D. Schulze, Eds. (Springer-Verlag, Berlin, 1976), pp. 19-31.
4. K. A. Granath, *J. Colloid Sci.* **13**, 308 (1958).
5. G. K. Ackers, *Biochemistry* **3**, 723 (1964).
6. L. G. Longworth, *J. Am. Chem. Soc.* **74**, 4155 (1952).
7. Suspension cultures of *A. pseudoplatanus* (sycamore maple) were obtained from D. T. A. Lamporn and were originally derived from cambial cells of this species. They were maintained on the M6E medium described by D. G. Pope [*Plant Physiol.* **59**, 894 (1977)]. The cells used for these experiments were in the exponential phase of growth (5 days after subculture).
8. Seeds of *R. sativus* were germinated on water-saturated filter paper. The radicle tips containing extending epidermal hair cells were excised and stained with neutral red to enhance the visibility of plasmolysis. Unfertilized ovules of *G. hirsutum* were cultured in vitro according to C. A. Beasley and I. P. Ting [*Am. J. Bot.* **60**, 130 (1973)]. Intact extending fibers were used after 8 days of culture and also were stained with neutral red. Fibers at this age possess only a primary wall. Palisade parenchyma cells of *X. strumarium* were isolated according to T. D. Sharkey and R. Raschke (*Plant Physiol.*, in press), and those of *C. communis* were obtained by peeling away the lower epidermis and scraping the cells gently into water with a fine dissecting needle. The palisade parenchyma cells were obtained from fully expanded leaves.
9. It should be noted that of the cell types examined here, only the leaf cells were obtained by mechanical disruption of the plant tissue; thus, we cannot exclude the possibility that the larger pore size observed by us may have resulted from the isolation procedure.
10. A. Frey-Wyssling and K. Mitrakos, *J. Ultrastruct. Res.* **3**, 228 (1959).
11. W. R. Haselton, *Tappi* **38** (No. 12), 716 (1955); E. F. Thode, J. W. Swanson, J. J. Becher, *J. Phys. Chem.* **62**, 1036 (1958); J. E. Stone, *Pulp Pap. Res. Inst. Can. Tech. Rep.* **382** (1964).
12. J. E. Stone and A. M. Scallan, *Pulp Pap. Res. Inst. Can. Tech. Rep.* **T288** (1968).
13. P. Gerhardt and J. A. Judge, *J. Bacteriol.* **87**, 945 (1964); R. Scherrer and P. Gerhardt, *ibid.* **107**, 718 (1971); J. R. Trevithick, R. L. Metznerberg, D. F. Costello, *ibid.* **92**, 1016 (1966).
14. W. D. Bauer, K. W. Talmadge, K. Keegstra, P. Albersheim, *Plant Physiol.* **51**, 174 (1973); G. E. Becker, P. A. Hui, P. Albersheim, *ibid.* **39**, 913 (1964); K. Keegstra, K. W. Talmadge, W. D. Bauer, P. Albersheim, *ibid.* **51**, 188 (1973).
15. M. K. Brakke and L. G. Nickell, *Arch. Biochem. Biophys.* **32**, 28 (1951); O. L. Gamborg and D. E. Eveleigh, *Can. J. Biochem.* **46**, 417 (1968); K. Keegstra and P. Albersheim, *Plant Physiol.* **45**, 675 (1970); A. E. Oleson, E. T. Clark, A. M. Janski, *Phytochemistry* **13**, 2113 (1974); J. Strauss and W. A. Campbell, *Life Sci.* **1**, 50 (1963).
16. R. E. Paull and R. L. Jones, *Aust. J. Plant Physiol.* **5**, 457 (1978).
17. D. H. Northcote and J. D. Pickett-Heaps, *Biochem. J.* **98**, 159 (1966).
18. R. E. Paull and R. L. Jones, *Z. Pflanzenphysiol.* **79**, 154 (1976).
19. G. A. Strobel, *Annu. Rev. Plant Physiol.* **25**, 541 (1974).
20. A. R. Ayers, J. Ebel, B. Valent, P. Albersheim, *Plant Physiol.* **57**, 760 (1976).
21. L. Sequeira, *Annu. Rev. Phytopathol.* **16**, 453 (1978).
22. This work was supported by DOE contract EY-76-02-C-1338 and by Cotton Incorporated.

22 February 1979; revised 4 June 1979

## [<sup>3</sup>H]GABA Binding in Brains from Huntington's Chorea Patients: Altered Regulation by Phospholipids?

**Abstract.** *Binding sites for tritium-labeled  $\gamma$ -aminobutyric acid (GABA) in cerebellar cortex of Huntington's chorea patients have an increased affinity but unaltered maximum capacity as compared to binding sites in tissue from control patients. A similar binding pattern is produced in control membranes by treatment with Triton X-100, phospholipase C, or glycerophosphoethanolamine. Thus, it is likely that phospholipids or their metabolites regulate the accessibility of the GABA binding site and that this regulation is abnormal in Huntington's chorea.*

In the striatum and some other brain areas from Huntington's chorea patients, there is a large loss of neurons that contain  $\gamma$ -aminobutyric acid (GABA) and its synthesizing enzyme L-glutamic acid decarboxylase (1). Pharmacological attempts at GABA replacement therapy in Huntington's chorea have been mainly inconclusive (2), although some success in treatment of recently diagnosed patients with a GABA-mimetic agent has been reported (3). The potential success of GABA replacement therapy is dependent on the integrity of GABA receptors. Initial reports on GABA receptors (as estimated by [<sup>3</sup>H]GABA binding) in Huntington's disease indicated that these receptors are largely intact (4). However, subsequent studies have demonstrated that in the striatum there is a severe loss of GABA receptors in this disease (5, 6). Despite this large loss of striatal GABA receptors, GABA replacement therapy may still be efficacious (i) if GABA receptors outside the striatum are relevant to treatment of the disease or (ii) if the remaining GABA receptors are super-sensitive. The present report focuses on the second possibility.

The cerebellar cortex was chosen for study because (i) a large amount of homogeneous tissue is available, whereas the degeneration and gliosis occurring in the striatum often do not leave enough tissue for detailed study; (ii) clinical signs of cerebellar dysfunction are often present in Huntington's disease (7); and (iii) several of the neurochemical changes typical in Huntington's disease

occur in the cerebellum, although they are less marked than in the striatum (1, 8). Despite the neurochemical and clinical observations of cerebellar dysfunction in Huntington's disease, the tissue appears normal. However, in the juvenile form of the disease, severe cerebellar degeneration may occur (9). These results suggest that in the adult form changes occur in the cerebellum which are not detected in light microscopic examination.

The kinetics of GABA receptors were studied by the [<sup>3</sup>H]GABA binding technique as adapted in our laboratory (10). The materials from control and Huntington's patients were matched for age and postmortem time. Tissue from the same brains was used for all experiments. The clinical diagnosis of Huntington's disease was verified by histopathological examination in all cases. Concentrations of GABA for the binding assay (10) ranged from  $5 \times 10^{-9}$  to  $5 \times 10^{-7}M$ , and binding affinity was estimated from the dose-response, Scatchard, or Lineweaver-Burk plots. As all methods of data analysis yielded very similar results, only the kinetic parameters from the Scatchard analyses are reported. For all patients, only one slope and intercept was observed in the Scatchard plot.

The affinity of [<sup>3</sup>H]GABA binding to cerebellar membranes (Table 1) is increased (decreased  $K_d$ ) threefold in membranes prepared from Huntington's cerebellum as compared to controls; the tendency toward an increased number of binding sites is not statistically significant.

cant. The decreased  $K_d$  is in agreement with the decrease in the 50 percent inhibition concentration ( $IC_{50}$ ) reported by us for a different series of patients (5). These results indicate that the increase in binding of 25 nM [ $^3H$ ]GABA previously reported (5) is due to the shift in the binding curve. Such a shift resembles to some extent the alterations induced by Triton X-100 in rat brain preparations (11). Thus, homogenates from the current series of brains were incubated for 30 minutes at 37°C with 0.02 percent Triton X-100 and then the membranes were prepared as described (10). In preparations from normal brains, Triton X-100 treatment decreases the  $K_d$  for [ $^3H$ ]GABA binding without significantly altering  $B_{max}$  (Table 1). The kinetic parameters for [ $^3H$ ]GABA binding to cerebellar membranes from Huntington's patients are unaltered by the Triton X-100 treatment. The  $K_d$  and  $B_{max}$  for [ $^3H$ ]GABA binding to the Triton-treated normal membranes are virtually identical to those for the untreated membranes from Huntington's chorea patients. This observation, together with the lack of effect of Triton X-100 on the [ $^3H$ ]GABA binding to membranes from Huntington's patients, suggests that the change (or

changes) induced by Triton treatment of control membranes has already occurred in the Huntington's patients. Although most patients had been treated with neuroleptics, this is unlikely to be a factor in the changes in [ $^3H$ ]GABA binding because treatment of rats for 6 months with either haloperidol or clozapine only slightly alters the [ $^3H$ ]GABA binding to membranes prepared from cerebellar cortex (9). Also, two patients who had never received neuroleptics showed the same alterations in [ $^3H$ ]GABA binding as did the drug-treated patients.

A likely change in membrane structure induced by Triton X-100 is an alteration in the lipid components. In an attempt to reproduce this change by a more physiological means, homogenates were incubated with phospholipase C (0.001 unit), in a manner similar to that for Triton X-100, before membrane preparation. This treatment reproduced those changes observed with Triton X-100 (Table 1):  $K_d$  was reduced but  $B_{max}$  was not significantly altered for [ $^3H$ ]GABA binding in control membranes, whereas the kinetic parameters for membranes from Huntington's patients were unaltered.

Of the phospholipids that are abundant

in cerebral membranes, phosphatidylethanolamine is more likely to be involved with GABA receptor function than is either phosphatidylcholine or phosphatidylserine (12, 13). Phospholipase C hydrolysis of this substance would produce *o*-phosphoethanolamine. When incubated with human cerebellar membranes *o*-phosphoethanolamine slightly but not significantly altered the  $K_d$  for [ $^3H$ ]GABA binding in control and Huntington's chorea patients and was without effect on the changes induced by phospholipase C in the control membranes (Table 2). In contrast, glycerophosphoethanolamine (reaction product of phospholipase  $A_1$  plus  $A_2$  hydrolysis) decreased the  $K_d$  of [ $^3H$ ]GABA binding to normal membranes (Table 2). It did not alter the phospholipase C effect nor did it change the [ $^3H$ ]GABA binding kinetics for membranes from Huntington's patients.

These results suggest that (i) membrane phospholipids, especially phosphatidylethanolamine and its metabolites, may be involved in the pathology of Huntington's disease and (ii) normally, phosphatidylethanolamine or a closely related substance has a regulatory action on the affinity of (or access to) the [ $^3H$ ]GABA binding site. With regard to (i), the quantity of phospholipids has been reported to be low in striatal tissue but not in cortex from Huntington's chorea patients (14). To our knowledge, cerebellar cortex has not been examined. Other biochemical abnormalities observed in the cerebellar cortex reflect, to a lesser extent, the changes occurring in the striatum and substantia nigra (1).

The question of [ $^3H$ ]GABA binding interactions with phospholipids and related substances has been considered (12, 13). Phospholipase C but not phospholipase A or D increases GABA binding of a single, high concentration of [ $^3H$ ]GABA to cerebellar junctional complexes, and phosphatidylethanolamine (but not phosphatidylcholine or phosphatidylserine) inhibits [ $^3H$ ]GABA binding. Phospholipase C could act either by removing a phospholipid regulator (inhibitor) from the membrane receptor or by producing a reaction product that functions as an activator. From this and previous studies, it appears that both possibilities may occur. Glycerophosphoethanolamine content is elevated in postmortem material from brains from patients with Huntington's chorea (1, 9); this may partially explain the alteration in [ $^3H$ ]GABA binding (Table 2). At present we do not think that phospholipids are inhibitors acting directly at the binding site, but rather suspect that they con-

Table 1. Effect of Triton X-100 or phospholipase C on [ $^3H$ ]GABA binding to cerebellar membranes. Results are expressed as means  $\pm$  standard error of mean (S.E.M.). Kinetic parameters were calculated from Scatchard plots; statistical significance was determined by Student's *t*-test, two-tailed.

Treatment	Control patients (N = 8)		Huntington's chorea patients (N = 8)	
	$K_d$ (nM)	$B_{max}$ (fmole per mg of tissue)	$K_d$ (nM)	$B_{max}$ (fmole per mg of tissue)
Untreated tissue	101 $\pm$ 8	76 $\pm$ 13	37 $\pm$ 4*	90 $\pm$ 8
Triton X-100 (0.02 percent)	38 $\pm$ 3†	98 $\pm$ 15	31 $\pm$ 4	131 $\pm$ 15
Phospholipase C (0.001 unit)	44 $\pm$ 11	67 $\pm$ 9	31 $\pm$ 4	107 $\pm$ 11

\* $P < .001$  compared to controls. † $P < .001$  compared to untreated tissue.

Table 2. Effect of *o*-phosphoethanolamine or glycerophosphoethanolamine on [ $^3H$ ]GABA binding to membranes from cerebellar cortex of control or Huntington's chorea patients. Results are expressed as means  $\pm$  S.E.M. Data were analyzed by means of Scatchard plots and Student's two-tailed *t*-test. Data for untreated tissue are given in Table 1; N, number of brains.

Treatment	Control patients			Huntington's chorea patients		
	$K_d$ (nM)	$B_{max}$ (fmole per mg of tissue)	N	$K_d$ (nM)	$B_{max}$ (fmole per mg of tissue)	N
<i>o</i> -Phosphoethanolamine (2 $\mu$ M)	81 $\pm$ 7	78 $\pm$ 9	7	50 $\pm$ 4*	126 $\pm$ 16†	7
<i>o</i> -Phosphoethanolamine (2 $\mu$ M) + phospholipase (0.001 unit)	41 $\pm$ 8‡	65 $\pm$ 8	7	37 $\pm$ 4	104 $\pm$ 17	6
Glycerophosphoethanolamine (0.5 $\mu$ M)	56 $\pm$ 13§	60 $\pm$ 14	8	43 $\pm$ 6	93 $\pm$ 13	8
Glycerophosphoethanolamine (0.5 $\mu$ M) + phospholipase C (0.001 unit)	57 $\pm$ 15§	60 $\pm$ 14	8	36 $\pm$ 5	114 $\pm$ 14	7

\* $P < .05$  compared to controls. † $P < .001$  compared to controls. ‡ $P < .001$  compared to untreated tissue. § $P < .05$  compared to untreated tissue.

trol the access of hydrophilic molecules (such as GABA or muscimol) to the binding site by increasing lipid content in the environment. This contention is supported by the observation that Triton X-100 treatment increases the affinity for hydrophilic (that is, lipophobic) ligands such as GABA or muscimol but does not alter the affinity of lipophilic molecules (such as SL 76 002, a GABA-mimetic benzophenone) for the binding site (3, 12).

KENNETH G. LLOYD

Neuropharmacology Unit, Biology  
Department, Laboratoires de Recherche  
Synthélabo, 92220 Bagneux, France

LYNNE DAVIDSON

Clarke Institute of Psychiatry,  
Toronto, Ontario M5T 1R8, Canada

#### References and Notes

1. E. D. Bird and L. L. Iversen, *Brain* **97**, 457 (1974); E. G. McGeer and P. L. McGeer, *J. Neurochem.* **26**, 65 (1976); T. L. Perry, S. Hansen, M. Kloster, *N. Engl. J. Med.* **288**, 337 (1973); W. L. Stahl and P. D. Swanson, *Neurology* **24**, 813 (1974).
2. T. N. Chase and C. A. Tamminga, in *GABA-Neurotransmitters*, H. Kofod, P. Krosggaard-Larsen, J. Scheel-Kruger, Eds. (Munksgaard, Copenhagen, 1979), p. 283; I. Shoulson, T. N. Chase, E. Roberts, J. Van Balgooy, *N. Engl. J. Med.* **293**, 504 (1975).
3. G. Bartholini, B. Scatton, B. Zivkovic, K. G. Lloyd, in *GABA-Neurotransmitters*, H. Kofod, P. Krosggaard-Larsen, J. Scheel-Kruger, Eds. (Munksgaard, Copenhagen, 1979), p. 326.
4. S. J. Enna, J. P. Bennet, D. B. Bylund, S. H. Snyder, E. D. Bird, L. L. Iversen, *Brain Res.* **116**, 531 (1976); S. J. Enna, E. D. Bird, J. P. Bennet, D. B. Bylund, H. I. Yamamura, L. L. Iversen, S. H. Snyder, *N. Engl. J. Med.* **294**, 1305 (1976).
5. K. G. Lloyd, S. Dreksler, E. D. Bird, *Life Sci.* **21**, 747 (1977).
6. L. L. Iversen, E. D. Bird, E. Spokes, S. N. Nicholson, C. J. Suckling, in *GABA-Neurotransmitters*, H. Kofod, P. Krosggaard-Larsen, J. Scheel-Kruger, Eds. (Munksgaard, Copenhagen, 1979), p. 179; R. W. Olsen and P. C. Van Ness, in *Second International Huntington's Disease Symposium*, T. N. Chase, N. Wexler, A. Barbeau, Eds. (Raven, New York, in press); T. D. Reisine, G. J. Wastek, K. Beaumont, F. M. Chen, E. D. Bird, H. I. Yamamura, in *ibid.*
7. C. D. Marsden and E. Zarafian, personal communication.
8. T. L. Perry, S. Hansen, D. Lesk, M. Kloster, in *Huntington's Chorea, 1872-1972*, A. Barbeau, T. N. Chase, G. W. Paulson, Eds. (Raven, New York, 1973), p. 609.
9. R. K. Byers, F. H. Gilles, C. Fung, *Neurology* **23**, 561 (1973); K. M. Earle, in *Huntington's Chorea, 1872-1972*, A. Barbeau, T. N. Chase, G. W. Paulson, Eds. (Raven, New York, 1973), p. 341; G. K. Klintworth, in *ibid.*, p. 353.
10. S. J. Enna and S. H. Snyder, *Brain Res.* **100**, 81 (1975); K. G. Lloyd, L. Shemen, O. Hornykiewicz, *ibid.* **127**, 269 (1977). Membranes were prepared from human cerebellar cortex by homogenizing (Polytron) a block of frozen tissue (100 to 300 mg; visible blood vessels and white matter removed) in deionized water. The suspension was left at room temperature for 30 minutes and then centrifuged at 48,000g for 10 minutes. The pellet was washed twice in deionized water, and the final pellet was resuspended in 0.05M potassium phosphate buffer (pH 7.2) to a concentration of 40 mg of starting tissue per milliliter of buffer (approximately 2 mg of protein per milliliter). The [<sup>3</sup>H]GABA binding assay was performed at 0°C in tubes containing 2.0 ml of 0.05M potassium phosphate buffer (pH 7.2), 0.5 ml of membrane preparation, 25 nM [<sup>3</sup>H]GABA (New England Nuclear), and nonradioactive GABA to the desired concentration. Blanks for determining nonspecific binding contained 1.0 mM GABA. After 5 minutes of incubation the tubes were centrifuged at 48,000g for 15 minutes, the supernatants were discarded, and the pellet was superficially rinsed. The tubes were then drained, the interiors dried, and the pellet dissolved with Protosol (New England Nuclear). After addition of 10 ml of Aquasol (New England Nuclear) and 0.1 ml of glacial acetic acid the samples were monitored for radioactivity in a Nuclear Chicago Mark I liquid scintillation counter. The postmortem intervals and storage time were similar for tissue from Huntington's chorea and control patients.
11. K. G. Lloyd, M. Shibuya, L. Davidson, O. Hornykiewicz, in *Nonstriatal Dopaminergic Neurons*, E. Costa and G. L. Gessa, Eds. (Raven, New York, 1977), p. 409.
12. S. J. Enna and S. H. Snyder, *Mol. Pharmacol.* **13**, 442 (1977); G. A. R. Johnston and S. M. E. Kennedy, in *Amino Acids as Chemical Transmitters*, F. Fonnum, Ed. (Plenum, New York, 1978), p. 507.
13. G. T. Giambalvo and P. Rosenberg, *Biochim. Biophys. Acta* **436**, 741 (1976).
14. P. F. Borri, W. M. Op Den Velde, G. J. M. Hooghwenkel, G. W. Bruyn, *Neurology* **17**, 172 (1973); W. T. Norton, K. Iqbal, C. Tiffany, I. Tellez-Nagel, *ibid.* **23**, 812 (1978).

19 January 1979; revised 10 April 1979

## Vibrations: Their Signal Function for a Spider Kleptoparasite

**Abstract.** *The stealing behavior of Argyrodes elevatus suggests that this kleptoparasitic spider monitors the movements and the hunting success of its web-building host. Wrapping of prey by the host regularly elicits raids from the kleptoparasite. The prey-catching activities of the host generate vibrations that were recorded with a position-sensing photodiode. The recordings indicated that wrapping movements produce a characteristic pattern of vibrations.*

Tropical spiders of the theridiid genus *Argyrodes* Simon inhabit the webs of other spiders (1). The kleptoparasitic *Argyrodes elevatus* Taczanowski constructs no web of its own but primarily uses the snares of the orb-weaving spiders *Nephila clavipes* and *Argiope argentata* to secure its food. Fine threads connect its resting place, 20 to 30 cm outside the host's capture area (2), with the hub and several radii of the host's web. The kleptoparasites move along these

lines either in search of small insects entangled in the sticky spiral, but neglected by the host, or to steal large prey items caught and stored by the host (3, 3a, 4). Raids for stored prey packets are triggered by the host's prey-catching movements, and a distinct stealing behavior is displayed by the kleptoparasites, indicating a high degree of specialization toward either host species (4).

While studying the stealing behavior of *Argyrodes* (4), I subjected hosts and

kleptoparasites to experiments in which dead prey was presented on the tip of a vibrator but often retrieved from the web before the host reached and "caught" it, thus simulating prey escape. Only in a few instances (9 percent;  $N = 100$ ) did the kleptoparasites venture into a raid if the host ran toward the prey and searched but did not succeed in catching it. In contrast, a raid was regularly elicited (86 percent;  $N = 518$ ) if the prey was captured by the host. Close observations, as well as film analysis of the movements of hosts and kleptoparasites during the experiments, showed that in most cases the kleptoparasites started a raid the instant the prey was wrapped by the host. Since the vision of most web-building spiders is poor (5) and the use of acute olfaction has not been demonstrated, it is generally assumed (6) that vibrations are of major importance for these spiders. My experiments suggest that vibrations generated by the host during the wrapping sequence of prey capture were of crucial significance to the kleptoparasites. The prominence of these wrapping vibrations in the vibratory pattern of prey capture will be demonstrated.

I employed three methods for recording the vibrations of silken threads to investigate the pattern of vibrations generated by the host spiders during prey catching (7, 8). The best results—recording of large as well as small translocations of a single web strand—were obtained with a position-sensing photodetector (9).

A beam of parallel light is sent onto a reflector plate (3M Scotch-Lite High Gain Foil) placed at the hub of the spider web. The returned beam passes through a 100-mm macrolens onto the position-sensing silicon photodiode (Scotty Barrier PIN-SC 10, United Tech.) housed in a camera case. Movements of the reflector are displayed as magnified alterations of a cathode-ray beam. Since the reflecting angle is 0° to 1°, small twists of the reflector influence only the signal amplitude, but do not otherwise alter the signals. To minimize inertial effects, the reflector plate (0.5 mg, 1 to 2 mm<sup>2</sup>) is not fixed directly to the *Argyrodes* signal line but is attached to the intersection of a radius and spiral thread at points where signal threads originate. It is assumed (10) that the taut signal thread transmits vibrations from its point of attachment at the radius to the receiver with little alteration. Although vibrations in the spider web travel along the radii as longitudinal, transversal, and torsion translations (11), I measured only the longitudinal vector (12).

Figure 1 shows the pattern of vibra-